Marksans Pharma (MARKSANS) — Announcement

📢 Key Event
Q1FY27 PAT surged 173.9% YoY to ₹159 crore

🔄 What Changed
PAT growth of 173.9% YoY

🔮 What's Next
Expand OTC revenue through innovation and geographic expansion

💡 Investor Takeaway
Strong profitability growth and cash position validate expansion strategy, but international revenue diversification remains a focus area

⚠️ Risks
Rest of World revenue declined 36.8% YoY

Marksans Pharma reported a 35.6% YoY revenue jump to ₹841 crore in Q1FY27, with PAT surging 173.9% to ₹159 crore and EBITDA margin expanding 919 bps to 25.3%, driven by UK/Europe growth (74.7% YoY) and the QliniQ acquisition. Cash reserves rose to ₹1,058 crore, supporting continued European expansion and OTC innovation amid strong global market tailwinds.

📄 View Original Announcement (PDF)

📊 Stock Analysis — MARKSANS ✨ Ask AI About This

About Marksans Pharma Limited (MARKSANS)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹14,612.26 Cr P/E: 28.3 ROE: 17.2% ROCE: 23.4% Div Yield: 0.28%

View full MARKSANS stock details →

📡 Get AI alerts when MARKSANS files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track MARKSANS — Free

💡 Ask AI about this filing

"How will Rest of World revenue decline impact overall growth targets?" "What is the expected timeline for QliniQ integration contributing to margins?" "How does OTC expansion affect the company's long-term margin structure?"

Ask AI Free →

📊 More MARKSANS filings

See all MARKSANS filings →

🔥 Also filed on 12 August 2026

DBL Dilip Buildcon Limited Corporate Action NITCO Nitco Limited Financial Results KPIGREEN KPI Green Energy Limited Financial Results SDBL Som Distilleries & Breweries Limited Financial Results CONSOFINVT Consolidated Finvest & Holdings Limited Corporate Action TOUCHWOOD Touchwood Entertainment Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when MARKSANS files new disclosures

Track MARKSANS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MARKSANS — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd